Yahoo Finance 3 High Insider Ownership US Stocks With Up To 55% Revenue Growth
Amidst a robust week for U.S. stocks, fueled by significant advancements in AI and cloud computing from major technology firms, the market landscape appears increasingly conducive to exploring growth opportunities. In this context, companies with high insider ownership can be particularly compelling, as they often signal strong confidence from those who know the business best.
Top 10 Growth Companies With High Insider Ownership In The United States
Name | Insider Ownership | Earnings Growth |
GigaCloud Technology (NasdaqGM:GCT) | 26.6% | 21% |
PDD Holdings (NasdaqGS:PDD) | 32.1% | 22.2% |
Atour Lifestyle Holdings (NasdaqGS:ATAT) | 26% | 28.2% |
Li Auto (NasdaqGS:LI) | 29.3% | 21.4% |
Super Micro Computer (NasdaqGS:SMCI) | 14.3% | 40.2% |
Bridge Investment Group Holdings (NYSE:BRDG) | 11.8% | 98% |
EHang Holdings (NasdaqGM:EH) | 33% | 97.1% |
Carlyle Group (NasdaqGS:CG) | 29.2% | 23.6% |
ZKH Group (NYSE:ZKH) | 17.7% | 91.8% |
BBB Foods (NYSE:TBBB) | 23.6% | 75.4% |
We'll examine a selection from our screener results.
AvePoint
Simply Wall St Growth Rating: ★★★★☆☆
Overview: AvePoint, Inc. operates a cloud-native data management software platform across North America, Europe, the Middle East, Africa, and Asia Pacific with a market capitalization of approximately $1.57 billion.
Operations: The company generates its revenue primarily from its software and programming segment, which amounted to $286.79 million.
Insider Ownership: 37%
Revenue Growth Forecast: 16.5% p.a.
AvePoint, a company with high insider ownership, reported significant improvements in its financial performance for Q1 2024, with revenue increasing to US$74.53 million from US$59.57 million year-over-year and a reduced net loss of US$1.72 million compared to US$9.2 million previously. The firm anticipates continued growth, projecting revenues between US$314.3 million and US$320.3 million for the full year 2024, marking an approximate 17% increase at the midpoint from prior forecasts. This outlook aligns with AvePoint's strategic enhancements and operational adjustments reflected in recent bylaw changes aimed at aligning with new Delaware law provisions for officer exculpation.
Krystal Biotech
Simply Wall St Growth Rating: ★★★★★☆
Overview: Krystal Biotech, Inc. is a commercial-stage biotechnology company based in the United States that focuses on discovering, developing, and commercializing genetic medicines for rare diseases, with a market capitalization of approximately $4.66 billion.
Operations: The company generates its revenue by focusing on genetic medicines for rare diseases in the U.S.
Insider Ownership: 11.5%
Revenue Growth Forecast: 34.8% p.a.
Krystal Biotech, a growth company with high insider ownership, recently showcased its recovery by reporting a net income of US$0.932 million for Q1 2024, contrasting sharply with a net loss the previous year. The company's revenue is projected to grow at 34.8% annually, outpacing the US market forecast of 8.3%. Despite this promising outlook and substantial recent advancements in its clinical trials, such as the initiation of KYANITE-1 for lung tumors and achieving Fast Track Designation from the FDA, Krystal faces challenges including high share price volatility and shareholder dilution over the past year.
Click to explore a detailed breakdown of our findings in Krystal Biotech's earnings growth report.
Our valuation report unveils the possibility Krystal Biotech's shares may be trading at a premium.
Madrigal Pharmaceuticals
Simply Wall St Growth Rating: ★★★★★☆
Overview: Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in the United States that specializes in developing treatments for non-alcoholic steatohepatitis (NASH), with a market capitalization of approximately $4.51 billion.
Operations: The company focuses on developing treatments for non-alcoholic steatohepatitis (NASH) and does not report specific revenue segments.
Insider Ownership: 10.7%
Revenue Growth Forecast: 55.7% p.a.
Madrigal Pharmaceuticals, despite a significant net loss of US$147.54 million in Q1 2024, remains focused on growth through innovation with the introduction of Rezdiffra, the first FDA-approved treatment for NASH with moderate to advanced liver fibrosis. The company's recent shelf registration and follow-on equity offerings totaling over US$1.9 billion suggest aggressive capital raising strategies to support its expansion. While insider ownership aligns interests with shareholders, financial performance and market dilution present ongoing challenges.
Make It Happen
Reveal the 187 hidden gems among our Fast Growing US Companies With High Insider Ownership screener with a single click here.
Already own these companies? Bring clarity to your investment decisions by linking up your portfolio with Simply Wall St, where you can monitor all the vital signs of your stocks effortlessly.
Discover a world of investment opportunities with Simply Wall St's free app and access unparalleled stock analysis across all markets.
Want To Explore Some Alternatives?
Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Companies discussed in this article include NasdaqGS:AVPT NasdaqGS:KRYS and NasdaqGS:MDGL.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
